Mixed hepatoblastoma and teratoma of the liver in a 3-year-old child: a unique combination and clinical challenge
© Moll et al; licensee BioMed Central Ltd. 2009
Received: 28 July 2009
Accepted: 12 November 2009
Published: 12 November 2009
Primary liver tumors in children are rare with malignant hepatoblastoma being the most common neoplasm. In this report, we describe the diagnosis and clinical management of a large liver tumor in a 3-year-old child that displayed the features of both, conventional hepatoblastoma and malignant teratoma. Pathological assessment on a pre-operative bioptical specimen showed an immature teratoid tumor with no area of hepatoblastic differentiation present. Histological and immunhistological examination of the resected tumor specimen additionally showed tumor areas of very different differentiation pattern intermixed with each other, namely areas of hepatoblastoma-typical and neuroblastoma-like morphology as well as areas of rhadomyosarcomatous differentiation.
After chemotherapy the tumor size increased and an extended right hemihepatectomy was performed. Post-operatively, the general condition of the child improved and adjuvant chemotherapy was started two weeks later. 36 months after initial diagnosis the patient is healthy, in good general condition, and without any sign of residual tumor disease.
Overall, we describe the diagnosis and clinical management of a large liver tumor in a 3-year-old child that displayed the features of both, conventional hepatoblastoma and malignant teratoma and was designated as mixed hepatoblastoma and teratoma. Though mesenchymal tumor portions can occur within hepatoblastomas, most commonly osteoid or chondroid, our case is different as it presents a large spectrum of mesenchymal and epithelial differentiation pattern in most of the lesion.
Primary liver tumors in children are rare. The liver is embryologically derived from both meso- and endodermal tissues and, thus, can develop a wide variety of both benign and malignant neoplasms. Hepatoblastoma is the most common malignant hepatic neoplasm of childhood, representing about 75% of the primary liver tumors in children in Western countries. Hepatic (benign or malignant) teratoma is an extremely rare tumor with only single cases reported world-wide [1–4]. In this report, we describe the diagnosis and clinical management of a mixed hepatoblastoma and teratoma of the liver in a 3-year-old boy.
Clinical History and Histological Findings
Pathological assessment on a bioptical specimen showed an immature teratoid tumor with no area of hepatoblastic differentiation present. After a 5-day PEI chemotherapy following the MAKEI 96 protocol of the German Society for Pediatric Oncology and Hematology (GPOH)  AFP decreased, but the tumor size increased to 14 × 14 × 20 cm. An extended right hemihepatectomy was performed. The gross surgical specimen measured 23.5 × 16.8 × 11 cm (1915 g) with a lesion size of 16 × 14 × 11 cm (fig. 1d) and a minimal tumor-free margin of 0.3 cm. The tumor was encapsulated and macroscopically showed multiple cysts with a diameter of up to 1.5 cm, about 40% of the tumor was necrotic.
The patient recovered well and showed no signs of further tumor disease 36 months postoperatively.
Immunohistochemical analysis (antibodies are listed in table 1; results in table 2) revealed expression of HepPar-1 selectively in the hepatoblastic cells (fig. 2c) including a significant amount of the cells within the necrotic tumor areas (fig. 2d) suggesting that mostly the hepatoblastic tumor portions were showing regression after chemotherapy. No expression of AFP was found in any tumor portion. The spindle-shaped cells presenting focally cross-striation (fig. 2h: insert) expressed strongly desmin (fig. 2j), sarcomer actin (fig. 2k) and partly myogenin (fig. 2i) in line with the rhabdomyosarcomatous phenotype of the cells. The gland-like structures expressed epithelial cytokeratins (KL-1), particularly cytokeratins 7 (fig. 2n) and 19 (fig. 2o) similar to bile duct epithelia. CK5/6 was specifically positive in the areas of squameous differentiation (fig. 2l). The small cell tumor component embedded in a neurofibril-like material was positive for synaptophysin (fig. 2f), neuron-specific enolase (NSE), S-100 protein (fig. 2g), and CD56, which confirmed its neuroblastic differentiation. CD-99 as well as TTF-1 (thyroid transcription factor-1) was negative. The proliferation rate was 5 to 10% except for in the spindle-cell areas, which showed an increased proliferation rate (up to 30%).
FISH analysis demonstrated no amplification of the MYCN-oncogene, which would have been an indicator of a poor prognosis.
Post-operatively, the general condition of the child improved and the first of four 10-day IPA chemotherapy cycles following the HB 99 protocol of the GPOH was started two weeks later. 36 months after initial diagnosis the patient is healthy, in good general condition, and without any sign of residual tumor disease.
Hepatoblastoma is a rare, but the most common hepatic malignancy of childhood with a peak incidence from 6 months to 3 years. The etiology of hepatoblastoma is unknown, but it has been associated with Wiedemann-Beckwith syndrome, familial adenomatosis polyposis coli, prematurity and low birth weight. Hepatoblastomas are well-defined, solid, mostly intrahepatical lesions. Lymphatic and hematogenic metastases occur in advanced disease stages with the latter mostly involving the lungs. AFP levels are nearly always elevated in hepatoblastomas and are correlated in most cases with the stage of the disease ; also the rate of decline of AFP during treatment is of prognostic value. The decrease of AFP during chemotherapy, despite an increase in tumor size in our case, is at first sight unusual, but most likely reflects a rather high chemosensitivity of the hepatoblastoma tumor portions. In the teratoma, areas kept proliferating and were hardly affected. Correspondingly, the cells in the areas of tumor necrosis were at least in part still positive for HepPar-1.
Teratomas are rare neoplasms (incidence 0.7/100.000 children/year) with tissue derivatives of all three germ layers. Teratomas mostly occur in the ovaries, the sacrococcygeal region, the testes, and the central nerval system and only rarely in other locations with less than 5% occurring in the abdomen . Teratomas are thought to have been present since birth, or even before birth, and are therefore considered as congenital tumors. In the liver, only single cases of (benign or malignant) teratomas have been described [1–4].
Our case represents a nearly unique combination of both tumor entities, hepatoblastoma and malignant teratoma in a young boy. Though mesenchymal tumor portions can occur within hepatoblastomas, most commonly osteoid or chondroid , our case is different as it presents a large spectrum of mesenchymal and epithelial differentiation pattern in most of the lesion. Obviously, the dispute whether to call such a lesion mixed hepatoblastoma and teratoma or teratoid hepatoblastoma  might be mostly semantic. In our case, in which most of the lesion represented teratoma, however, we clearly prefer to talk about a mixed or combined neoplasm, namely mixed hepatoblastoma and teratoma.
The treatment of the presented mixed hepatoblastoma and teratoma of the liver was based on a combined systemic chemotherapy and surgery. Therapies of such a mixed tumor tissue have not been described yet, but children with hepatoblastomas have nowadays, due to the new therapy modalities, a rather good prognosis with a 5-year survival rate of over 70%  with curative surgery being the primary treatment of all pediatric liver tumors especially in the absence of metastatic disease. Systemic chemotherapy is beneficial as metastases are detectable at diagnosis in about 20% of all patients and most children suffer tumor recurrence after surgery alone.
In summary, we report on the diagnosis and clinical management of to our knowledge the second case of a mixed hepatoblastoma and teratoma in a young boy . Clearly, this represents a rare facet of embryonic tumors within the liver. This case as well as similar cases with a very peculiar tumor biology  documents the importance of adequate sampling of tumor material in all cases of heterogenous tumor differentiation in order not to miss minor, but relevant tumor portions. Management, as far as it can be estimated from a single case, appears to be along the guidelines valid for hepatoblastoma alone with, however, the caveat that the (applied) chemotherapy was only effective in the hepatoblastoma areas and not the teratoma portion of the tumor.
- Verma M, Agarwal S, Mohta A: Primary mixed germ cell tumour of the liver--a case report. Indian J Pathol Microbiol. 2003, 46: 658-9.PubMedGoogle Scholar
- Nirmala V, Chopra P, Machado NO: An unusual adult hepatic teratoma. Histopathology. 2003, 43: 306-8. 10.1046/j.1365-2559.2003.01675.x.View ArticlePubMedGoogle Scholar
- Winter TC, Freeny P: Hepatic teratoma in an adult. Case report with a review of the literature. J Clin Gastroenterol. 1993, 17: 308-10. 10.1097/00004836-199312000-00009.View ArticlePubMedGoogle Scholar
- Meyers RL: Tumors of the liver in children. Surg Oncol. 2007, 16: 195-203. 10.1016/j.suronc.2007.07.002.View ArticlePubMedGoogle Scholar
- Schneider DT, Calaminus G, Reinhard H, Gutjahr P, Kremens B, Harms D, et al.: Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96. J Clin Oncol. 2000, 18: 832-9.PubMedGoogle Scholar
- Ortega JA, Krailo MD, Haas JE, King DR, Ablin AR, Quinn JJ, et al.: Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol. 1991, 9: 2167-76.PubMedGoogle Scholar
- Schnater JM, Kuijper CF, Zsiros J, Heij HA, Aronson DC: Pre-operative diagnostic biopsy and surgery in paediatric liver tumours--the Amsterdam experience. Eur J Surg Oncol. 2005, 31: 1160-5. 10.1016/j.ejso.2005.07.012.View ArticlePubMedGoogle Scholar
- Manivel C, Wick MR, Abenoza P, Dehner LP: Teratoid hepatoblastoma. Cancer. 1986, 57: 2168-74. 10.1002/1097-0142(19860601)57:11<2168::AID-CNCR2820571115>3.0.CO;2-M.View ArticlePubMedGoogle Scholar
- Roebuck DJ, Perilongo G: Hepatoblastoma: an oncological review. Pediatr Radiol. 2006, 36: 183-6. 10.1007/s00247-005-0064-3.View ArticlePubMedGoogle Scholar
- Conrad RJ, Gribbin D, Walker NI, Ong TH: Combined cystic teratoma and hepatoblastoma of the liver. Probable divergent differentiation of an uncommitted hepatic precursor cell. Cancer. 1993, 72: 2910-3. 10.1002/1097-0142(19931115)72:10<2910::AID-CNCR2820721009>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Armah HB, Parwani AV, Perepletchikov AM: Synchronous primary carcinoid tumor and primary adenocarcinoma arising within mature cystic teratoma of horseshoe kidney: a unique case report and review of the literature. Diagn Pathol. 2009, 4: 17-10.1186/1746-1596-4-17.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.